Amphastar Pharmaceuticals (AMPH) vs Generate Biomedicines (GENB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Generate Biomedicines is the larger company by market cap ($1.23 billion vs $1.20 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMPH | GENB |
|---|---|---|
| Share price | $28.25 | $9.54 |
| Market cap | $1.20B | $1.23B |
| 1-day change | +0.50% | -8.00% |
| YTD return | +5.49% | — |
| 1-year return | +8.61% | — |
| 5-year return | +41.89% | — |
| P/E ratio (TTM) | 12.96 | — |
| Forward P/E | 8.43 | — |
| EPS (TTM) | $2.18 | $-2.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $719.89M | — |
| Revenue growth (YoY) | -1.65% | — |
| Net income (latest FY) | $98.09M | — |
| Gross margin | 49.46% | — |
| Operating margin | 19.50% | — |
| Net margin | 13.63% | — |
| 52-week high | $31.00 | $22.67 |
| 52-week low | $16.65 | $9.40 |
| Distance from 52-week high | -8.87% | -57.92% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -13.27% | +183.02% |
| Average volume | 475.35K | 1.24M |
| Shares outstanding | 42.65M | 129.10M |
| Employees | 1,976 | 312 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Amphastar Pharmaceuticals
AMPH stock →Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,976 employees
About Generate Biomedicines
GENB stock →Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees
AMPH vs GENB FAQ
Which is bigger, Amphastar Pharmaceuticals or Generate Biomedicines?
Generate Biomedicines (GENB) is larger, with a market capitalization of $1.23B compared with $1.20B for Amphastar Pharmaceuticals (AMPH).
Are Amphastar Pharmaceuticals and Generate Biomedicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.